HEADER VIRAL PROTEIN/IMMUNE SYSTEM 23-DEC-21 7TC9 TITLE LOCALLY REFINED REGION OF SARS-COV-2 SPIKE IN COMPLEX WITH ANTIBODY TITLE 2 A19-46.1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: SPIKE PROTEIN S1; COMPND 3 CHAIN: B; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: HEAVY CHAIN OF ANTIBODY A19-46.1; COMPND 7 CHAIN: H; COMPND 8 ENGINEERED: YES; COMPND 9 MOL_ID: 3; COMPND 10 MOLECULE: LIGHT CHAIN OF ANTIBODY A19-46.1; COMPND 11 CHAIN: L; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: S, 2; SOURCE 6 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 13 MOL_ID: 3; SOURCE 14 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 15 ORGANISM_TAXID: 9606; SOURCE 16 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 17 EXPRESSION_SYSTEM_TAXID: 9606 KEYWDS SARS-COV-2, OMICRON, SPIKE, ANTIBODY, VIRAL PROTEIN, VIRAL PROTEIN- KEYWDS 2 IMMUNE SYSTEM COMPLEX EXPDTA ELECTRON MICROSCOPY AUTHOR T.ZHOU,P.D.KWONG REVDAT 2 19-OCT-22 7TC9 1 JRNL REVDAT 1 30-MAR-22 7TC9 0 JRNL AUTH T.ZHOU,L.WANG,J.MISASI,A.PEGU,Y.ZHANG,D.R.HARRIS,A.S.OLIA, JRNL AUTH 2 C.A.TALANA,E.S.YANG,M.CHEN,M.CHOE,W.SHI,I.T.TENG,A.CREANGA, JRNL AUTH 3 C.JENKINS,K.LEUNG,T.LIU,E.D.STANCOFSKI,T.STEPHENS,B.ZHANG, JRNL AUTH 4 Y.TSYBOVSKY,B.S.GRAHAM,J.R.MASCOLA,N.J.SULLIVAN,P.D.KWONG JRNL TITL STRUCTURAL BASIS FOR POTENT ANTIBODY NEUTRALIZATION OF JRNL TITL 2 SARS-COV-2 VARIANTS INCLUDING B.1.1.529. JRNL REF SCIENCE V. 376 N8897 2022 JRNL REFN ESSN 1095-9203 JRNL PMID 35324257 JRNL DOI 10.1126/SCIENCE.ABN8897 REMARK 2 REMARK 2 RESOLUTION. 5.08 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 SOFTWARE PACKAGES : CRYOSPARC, COOT, PHENIX, CRYOSPARC REMARK 3 RECONSTRUCTION SCHEMA : NULL REMARK 3 REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT REMARK 3 PDB ENTRY : 7MM0 REMARK 3 REFINEMENT SPACE : REAL REMARK 3 REFINEMENT PROTOCOL : RIGID BODY FIT REMARK 3 REFINEMENT TARGET : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL REMARK 3 REMARK 3 FITTING PROCEDURE : NULL REMARK 3 REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 5.080 REMARK 3 NUMBER OF PARTICLES : 79077 REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE REMARK 3 CORRECTION REMARK 3 REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL REMARK 3 REMARK 3 OTHER DETAILS: NULL REMARK 4 REMARK 4 7TC9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 18-JAN-22. REMARK 100 THE DEPOSITION ID IS D_1000261998. REMARK 245 REMARK 245 EXPERIMENTAL DETAILS REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE REMARK 245 SPECIMEN TYPE : NULL REMARK 245 REMARK 245 ELECTRON MICROSCOPE SAMPLE REMARK 245 SAMPLE TYPE : PARTICLE REMARK 245 PARTICLE TYPE : POINT REMARK 245 NAME OF SAMPLE : SARS-COV-2 SPIKE IN COMPLEX REMARK 245 WITH ANTIBODY A19-46.1, LOCAL REMARK 245 REFINEMENT. REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : 0.50 REMARK 245 SAMPLE SUPPORT DETAILS : NULL REMARK 245 SAMPLE VITRIFICATION DETAILS : BLOT FOR 2-3.5 SECONDS BEFORE REMARK 245 PLUGGING. REMARK 245 SAMPLE BUFFER : NULL REMARK 245 PH : 7.40 REMARK 245 SAMPLE DETAILS : NULL REMARK 245 REMARK 245 DATA ACQUISITION REMARK 245 DATE OF EXPERIMENT : NULL REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL REMARK 245 TEMPERATURE (KELVIN) : NULL REMARK 245 MICROSCOPE MODEL : FEI TITAN KRIOS REMARK 245 DETECTOR TYPE : OTHER REMARK 245 MINIMUM DEFOCUS (NM) : 1100.00 REMARK 245 MAXIMUM DEFOCUS (NM) : 2100.00 REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 NOMINAL CS : 2.70 REMARK 245 IMAGING MODE : BRIGHT FIELD REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 4000.00 REMARK 245 ILLUMINATION MODE : FLOOD BEAM REMARK 245 NOMINAL MAGNIFICATION : 105000 REMARK 245 CALIBRATED MAGNIFICATION : NULL REMARK 245 SOURCE : FIELD EMISSION GUN REMARK 245 ACCELERATION VOLTAGE (KV) : 300 REMARK 245 IMAGING DETAILS : NULL REMARK 247 REMARK 247 ELECTRON MICROSCOPY REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION REMARK 247 OF THE STRUCTURE FACTORS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, H, L REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OG1 THR L 5 O GLY L 23 2.08 REMARK 500 OH TYR H 32 OH TYR H 110 2.10 REMARK 500 O GLU L 164 OG SER L 180 2.15 REMARK 500 O MET H 113 OH TYR L 38 2.18 REMARK 500 NE2 GLN H 39 O LYS H 43 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 PRO H 132 CG PRO H 132 CD -0.365 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 CYS B 379 CA - CB - SG ANGL. DEV. = 7.8 DEGREES REMARK 500 PRO H 132 CA - N - CD ANGL. DEV. = -11.5 DEGREES REMARK 500 PRO H 132 CA - CB - CG ANGL. DEV. = -14.8 DEGREES REMARK 500 PRO H 132 N - CD - CG ANGL. DEV. = -20.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA B 344 72.81 51.14 REMARK 500 PHE B 347 -169.71 -125.93 REMARK 500 ASN B 354 63.05 61.70 REMARK 500 PHE B 392 -167.60 -125.16 REMARK 500 ASN B 477 -161.21 64.76 REMARK 500 LYS B 478 72.21 41.17 REMARK 500 LEU B 518 -163.04 57.35 REMARK 500 HIS B 519 34.71 -141.03 REMARK 500 VAL B 524 -69.05 -122.32 REMARK 500 CYS B 525 -114.69 -19.60 REMARK 500 MET H 34 -168.00 -162.78 REMARK 500 VAL H 48 -56.74 -121.18 REMARK 500 SER H 52 -153.85 -136.49 REMARK 500 TYR H 53 11.83 -64.86 REMARK 500 ASP H 54 60.07 67.39 REMARK 500 SER H 56 -62.08 -94.68 REMARK 500 LEU H 81 41.98 -101.60 REMARK 500 GLN H 82 127.46 -39.50 REMARK 500 TYR H 110 -169.87 46.71 REMARK 500 MET H 113 128.13 -34.25 REMARK 500 ASP H 114 -31.78 -133.81 REMARK 500 ASP H 157 49.48 34.89 REMARK 500 SER L 30 4.68 -63.77 REMARK 500 PHE L 34 108.92 -48.00 REMARK 500 THR L 53 -93.46 48.11 REMARK 500 ASP L 155 -95.84 57.35 REMARK 500 ASN L 173 36.22 -99.83 REMARK 500 ASN L 174 62.08 61.28 REMARK 500 GLU L 202 37.99 39.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 CYS B 379 TYR B 380 -141.85 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: EMD-25806 RELATED DB: EMDB REMARK 900 LOCALLY REFINED REGION OF SARS-COV-2 SPIKE IN COMPLEX WITH ANTIBODY REMARK 900 A19-46.1 DBREF 7TC9 B 332 526 UNP P0DTC2 SPIKE_SARS2 332 526 DBREF 7TC9 H 1 231 PDB 7TC9 7TC9 1 231 DBREF 7TC9 L 1 216 PDB 7TC9 7TC9 1 216 SEQADV 7TC9 ASP B 339 UNP P0DTC2 GLY 339 CONFLICT SEQADV 7TC9 LEU B 371 UNP P0DTC2 SER 371 CONFLICT SEQADV 7TC9 PRO B 373 UNP P0DTC2 SER 373 CONFLICT SEQADV 7TC9 PHE B 375 UNP P0DTC2 SER 375 CONFLICT SEQADV 7TC9 ASN B 417 UNP P0DTC2 LYS 417 CONFLICT SEQADV 7TC9 LYS B 440 UNP P0DTC2 ASN 440 CONFLICT SEQADV 7TC9 SER B 446 UNP P0DTC2 GLY 446 CONFLICT SEQADV 7TC9 ASN B 477 UNP P0DTC2 SER 477 CONFLICT SEQADV 7TC9 LYS B 478 UNP P0DTC2 THR 478 CONFLICT SEQADV 7TC9 ALA B 484 UNP P0DTC2 GLU 484 CONFLICT SEQADV 7TC9 ARG B 493 UNP P0DTC2 GLN 493 CONFLICT SEQADV 7TC9 SER B 496 UNP P0DTC2 GLY 496 CONFLICT SEQADV 7TC9 ARG B 498 UNP P0DTC2 GLN 498 CONFLICT SEQADV 7TC9 TYR B 501 UNP P0DTC2 ASN 501 CONFLICT SEQADV 7TC9 HIS B 505 UNP P0DTC2 TYR 505 CONFLICT SEQRES 1 B 195 ILE THR ASN LEU CYS PRO PHE ASP GLU VAL PHE ASN ALA SEQRES 2 B 195 THR ARG PHE ALA SER VAL TYR ALA TRP ASN ARG LYS ARG SEQRES 3 B 195 ILE SER ASN CYS VAL ALA ASP TYR SER VAL LEU TYR ASN SEQRES 4 B 195 LEU ALA PRO PHE PHE THR PHE LYS CYS TYR GLY VAL SER SEQRES 5 B 195 PRO THR LYS LEU ASN ASP LEU CYS PHE THR ASN VAL TYR SEQRES 6 B 195 ALA ASP SER PHE VAL ILE ARG GLY ASP GLU VAL ARG GLN SEQRES 7 B 195 ILE ALA PRO GLY GLN THR GLY ASN ILE ALA ASP TYR ASN SEQRES 8 B 195 TYR LYS LEU PRO ASP ASP PHE THR GLY CYS VAL ILE ALA SEQRES 9 B 195 TRP ASN SER ASN LYS LEU ASP SER LYS VAL SER GLY ASN SEQRES 10 B 195 TYR ASN TYR LEU TYR ARG LEU PHE ARG LYS SER ASN LEU SEQRES 11 B 195 LYS PRO PHE GLU ARG ASP ILE SER THR GLU ILE TYR GLN SEQRES 12 B 195 ALA GLY ASN LYS PRO CYS ASN GLY VAL ALA GLY PHE ASN SEQRES 13 B 195 CYS TYR PHE PRO LEU ARG SER TYR SER PHE ARG PRO THR SEQRES 14 B 195 TYR GLY VAL GLY HIS GLN PRO TYR ARG VAL VAL VAL LEU SEQRES 15 B 195 SER PHE GLU LEU LEU HIS ALA PRO ALA THR VAL CYS GLY SEQRES 1 H 231 GLN VAL GLN LEU VAL GLU SER GLY GLY GLY VAL VAL GLN SEQRES 2 H 231 PRO GLY ARG SER LEU ARG LEU SER CYS ALA ALA SER GLY SEQRES 3 H 231 PHE THR LEU SER SER TYR GLY MET HIS TRP VAL ARG GLN SEQRES 4 H 231 ALA PRO GLY LYS GLY LEU GLU TRP VAL ALA VAL ILE SER SEQRES 5 H 231 TYR ASP GLY SER ASN LYS TYR TYR VAL ASP SER VAL LYS SEQRES 6 H 231 GLY ARG PHE THR ILE SER ARG ASP ASN SER LYS ASN THR SEQRES 7 H 231 LEU TYR LEU GLN MET ASN SER LEU ARG ALA GLU ASP THR SEQRES 8 H 231 ALA VAL TYR TYR CYS ALA ARG GLY TRP ALA TYR TRP GLU SEQRES 9 H 231 LEU LEU PRO ASP TYR TYR TYR GLY MET ASP VAL TRP GLY SEQRES 10 H 231 GLN GLY THR THR VAL THR VAL SER SER ALA SER THR LYS SEQRES 11 H 231 GLY PRO SER VAL PHE PRO LEU ALA PRO SER SER LYS SER SEQRES 12 H 231 THR SER GLY GLY THR ALA ALA LEU GLY CYS LEU VAL LYS SEQRES 13 H 231 ASP TYR PHE PRO GLU PRO VAL THR VAL SER TRP ASN SER SEQRES 14 H 231 GLY ALA LEU THR SER GLY VAL HIS THR PHE PRO ALA VAL SEQRES 15 H 231 LEU GLN SER SER GLY LEU TYR SER LEU SER SER VAL VAL SEQRES 16 H 231 THR VAL PRO SER SER SER LEU GLY THR GLN THR TYR ILE SEQRES 17 H 231 CYS ASN VAL ASN HIS LYS PRO SER ASN THR LYS VAL ASP SEQRES 18 H 231 LYS LYS VAL GLU PRO LYS SER CYS ASP LYS SEQRES 1 L 216 GLN THR VAL VAL THR GLN GLU PRO SER PHE SER VAL SER SEQRES 2 L 216 PRO GLY GLY THR VAL THR LEU THR CYS GLY LEU SER SER SEQRES 3 L 216 GLY SER VAL SER THR ALA TYR PHE PRO SER TRP TYR GLN SEQRES 4 L 216 GLN THR PRO GLY GLN ALA PRO ARG THR LEU ILE TYR GLY SEQRES 5 L 216 THR ASN THR ARG SER SER GLY VAL PRO ASP ARG PHE SER SEQRES 6 L 216 GLY SER ILE LEU GLY ASN LYS ALA ALA LEU THR ILE THR SEQRES 7 L 216 GLY ALA GLN ALA ASP ASP GLU SER ASP TYR TYR CYS VAL SEQRES 8 L 216 LEU TYR MET GLY ARG GLY ILE VAL VAL PHE GLY GLY GLY SEQRES 9 L 216 THR LYS LEU THR VAL LEU GLY GLN PRO LYS ALA ALA PRO SEQRES 10 L 216 SER VAL THR LEU PHE PRO PRO SER SER GLU GLU LEU GLN SEQRES 11 L 216 ALA ASN LYS ALA THR LEU VAL CYS LEU ILE SER ASP PHE SEQRES 12 L 216 TYR PRO GLY ALA VAL THR VAL ALA TRP LYS ALA ASP SER SEQRES 13 L 216 SER PRO VAL LYS ALA GLY VAL GLU THR THR THR PRO SER SEQRES 14 L 216 LYS GLN SER ASN ASN LYS TYR ALA ALA SER SER TYR LEU SEQRES 15 L 216 SER LEU THR PRO GLU GLN TRP LYS SER HIS ARG SER TYR SEQRES 16 L 216 SER CYS GLN VAL THR HIS GLU GLY SER THR VAL GLU LYS SEQRES 17 L 216 THR VAL ALA PRO THR GLU CYS SER HET NAG B 601 14 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE FORMUL 4 NAG C8 H15 N O6 HELIX 1 AA1 PHE B 338 ASN B 343 1 6 HELIX 2 AA2 PRO B 384 ASN B 388 5 5 HELIX 3 AA3 ASP B 405 GLN B 409 5 5 HELIX 4 AA4 GLY B 416 ASN B 422 1 7 HELIX 5 AA5 THR H 28 TYR H 32 5 5 HELIX 6 AA6 VAL H 61 LYS H 65 5 5 HELIX 7 AA7 SER H 169 ALA H 171 5 3 HELIX 8 AA8 SER L 125 GLN L 130 1 6 HELIX 9 AA9 THR L 185 LYS L 190 1 6 HELIX 10 AB1 ALA L 211 SER L 216 1 6 SHEET 1 AA1 3 THR B 393 ILE B 402 0 SHEET 2 AA1 3 TYR B 508 GLU B 516 -1 O SER B 514 N TYR B 396 SHEET 3 AA1 3 VAL B 433 ASN B 437 -1 N TRP B 436 O ARG B 509 SHEET 1 AA2 2 LEU B 452 ARG B 454 0 SHEET 2 AA2 2 LEU B 492 SER B 494 -1 O ARG B 493 N TYR B 453 SHEET 1 AA3 2 TYR B 473 GLN B 474 0 SHEET 2 AA3 2 CYS B 488 TYR B 489 -1 O TYR B 489 N TYR B 473 SHEET 1 AA4 4 LEU H 4 SER H 7 0 SHEET 2 AA4 4 SER H 21 ALA H 24 -1 O SER H 21 N SER H 7 SHEET 3 AA4 4 THR H 78 TYR H 80 -1 O LEU H 79 N CYS H 22 SHEET 4 AA4 4 SER H 71 ASP H 73 -1 N ASP H 73 O THR H 78 SHEET 1 AA5 2 GLY H 10 VAL H 12 0 SHEET 2 AA5 2 VAL H 122 VAL H 124 1 O THR H 123 N GLY H 10 SHEET 1 AA6 3 GLU H 46 VAL H 50 0 SHEET 2 AA6 3 HIS H 35 ARG H 38 -1 N ARG H 38 O GLU H 46 SHEET 3 AA6 3 TYR H 95 CYS H 96 -1 O TYR H 95 N VAL H 37 SHEET 1 AA7 4 SER H 133 LEU H 137 0 SHEET 2 AA7 4 THR H 148 LYS H 156 -1 O LEU H 154 N PHE H 135 SHEET 3 AA7 4 TYR H 189 PRO H 198 -1 O VAL H 195 N LEU H 151 SHEET 4 AA7 4 VAL H 176 THR H 178 -1 N HIS H 177 O VAL H 194 SHEET 1 AA8 4 SER H 133 LEU H 137 0 SHEET 2 AA8 4 THR H 148 LYS H 156 -1 O LEU H 154 N PHE H 135 SHEET 3 AA8 4 TYR H 189 PRO H 198 -1 O VAL H 195 N LEU H 151 SHEET 4 AA8 4 VAL H 182 LEU H 183 -1 N VAL H 182 O SER H 190 SHEET 1 AA9 3 THR H 164 TRP H 167 0 SHEET 2 AA9 3 ILE H 208 HIS H 213 -1 O ASN H 212 N THR H 164 SHEET 3 AA9 3 THR H 218 LYS H 223 -1 O LYS H 222 N CYS H 209 SHEET 1 AB1 2 SER L 9 VAL L 12 0 SHEET 2 AB1 2 LYS L 106 VAL L 109 1 O THR L 108 N PHE L 10 SHEET 1 AB2 3 THR L 17 THR L 21 0 SHEET 2 AB2 3 LYS L 72 THR L 78 -1 O ILE L 77 N VAL L 18 SHEET 3 AB2 3 PHE L 64 SER L 65 -1 N SER L 65 O THR L 76 SHEET 1 AB3 3 THR L 17 THR L 21 0 SHEET 2 AB3 3 LYS L 72 THR L 78 -1 O ILE L 77 N VAL L 18 SHEET 3 AB3 3 ILE L 68 LEU L 69 -1 N LEU L 69 O LYS L 72 SHEET 1 AB4 4 THR L 48 TYR L 51 0 SHEET 2 AB4 4 SER L 36 TYR L 38 -1 N TRP L 37 O ILE L 50 SHEET 3 AB4 4 TYR L 89 TYR L 93 -1 O VAL L 91 N SER L 36 SHEET 4 AB4 4 VAL L 99 VAL L 100 -1 O VAL L 100 N LEU L 92 SHEET 1 AB5 4 SER L 118 PHE L 122 0 SHEET 2 AB5 4 ALA L 134 PHE L 143 -1 O SER L 141 N SER L 118 SHEET 3 AB5 4 SER L 180 LEU L 184 -1 O LEU L 182 N LEU L 136 SHEET 4 AB5 4 VAL L 163 THR L 165 -1 N GLU L 164 O TYR L 181 SHEET 1 AB6 4 SER L 118 PHE L 122 0 SHEET 2 AB6 4 ALA L 134 PHE L 143 -1 O SER L 141 N SER L 118 SHEET 3 AB6 4 TYR L 176 ALA L 178 -1 O ALA L 178 N ILE L 140 SHEET 4 AB6 4 SER L 169 LYS L 170 -1 N SER L 169 O ALA L 177 SHEET 1 AB7 4 SER L 157 PRO L 158 0 SHEET 2 AB7 4 VAL L 148 ALA L 154 -1 N ALA L 154 O SER L 157 SHEET 3 AB7 4 TYR L 195 HIS L 201 -1 O SER L 196 N LYS L 153 SHEET 4 AB7 4 SER L 204 VAL L 210 -1 O SER L 204 N HIS L 201 SSBOND 1 CYS B 336 CYS B 361 1555 1555 2.03 SSBOND 2 CYS B 379 CYS B 432 1555 1555 2.05 SSBOND 3 CYS B 391 CYS B 525 1555 1555 2.03 SSBOND 4 CYS B 480 CYS B 488 1555 1555 2.03 SSBOND 5 CYS H 22 CYS H 96 1555 1555 2.03 SSBOND 6 CYS H 153 CYS H 209 1555 1555 2.03 SSBOND 7 CYS L 22 CYS L 90 1555 1555 2.03 SSBOND 8 CYS L 138 CYS L 197 1555 1555 2.04 LINK ND2 ASN B 343 C1 NAG B 601 1555 1555 1.46 CISPEP 1 PHE H 159 PRO H 160 0 -1.67 CISPEP 2 GLU H 161 PRO H 162 0 -5.96 CISPEP 3 TYR L 144 PRO L 145 0 -0.97 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000